FibroGen Investor Relations Material
Latest events
Q4 2024
FibroGen
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from FibroGen Inc
Access all reports
FibroGen Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for serious unmet medical needs, particularly in areas like fibrosis, oncology, and anemia. The company’s lead products target conditions such as chronic kidney disease-related anemia and idiopathic pulmonary fibrosis. The company is headquartered in San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for FibroGen Inc
Q3 2024
FibroGen Inc
Q4 2024
FibroGen Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
FGEN
Country
🇺🇸 United States